Exam Name: | Artificial Intelligence Governance Professional | ||
Exam Code: | AIGP Dumps | ||
Vendor: | IAPP | Certification: | Artificial Intelligence Governance |
Questions: | 100 Q&A's | Shared By: | zack |
All of the following types of testing can help evaluate the performance of a responsible Al system EXCEPT?
CASE STUDY
Please use the following answer the next question:
A mid-size US healthcare network has decided to develop an Al solution to detect a type of cancer that is most likely arise in adults. Specifically, the healthcare network intends to create a recognition algorithm that will perform an initial review of all imaging and then route records a radiologist for secondary review pursuant Agreed-upon criteria (e.g., a confidence score below a threshold).
To date, the healthcare network has taken the following steps: defined its Al ethical principles: conducted discovery to identify the intended uses and success criteria for the system: established an Al governance committee; assembled a broad, crossfunctional team with clear roles and responsibilities; and created policies and procedures to document standards, workflows, timelines and risk thresholds during the project.
The healthcare network intends to retain a cloud provider to host the solution and a consulting firm to help develop the algorithm using the healthcare network's existing data and de-identified data that is licensed from a large US clinical research partner.
The most significant risk from combining the healthcare network’s existing data with the clinical research partner data is?
You are the chief privacy officer of a medical research company that would like to collect and use sensitive data about cancer patients, such as their names, addresses, race and ethnic origin, medical histories, insurance claims, pharmaceutical prescriptions, eating and drinking habits and physical activity.
The company will use this sensitive data to build an Al algorithm that will spot common attributes that will help predict if seemingly healthy people are more likely to get cancer. However, the company is unable to obtain consent from enough patients to sufficiently collect the minimum data to train its model.
Which of the following solutions would most efficiently balance privacy concerns with the lack of available data during the testing phase?
Which of the following Al uses is best described as human-centric?